Defunct Company
Total Trials
9
As Lead Sponsor
8
As Collaborator
1
Total Enrollment
1,059
NCT02798692
Trial to Evaluate Safety and Immunogenicity of a Vaccine Against HCMV
Phase: Phase 1
Role: Lead Sponsor
Start: Jun 30, 2016
Completion: Mar 31, 2018
NCT03629080
A Study of CMV Vaccine (HB-101) in Kidney Transplant Patients
Phase: Phase 2
Start: Dec 12, 2018
Completion: Jun 22, 2022
NCT04180215
A Phase 1/2 Study in Patients With HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma and Other Cancers
Phase: Phase 1/2
Start: Dec 11, 2019
Completion: Jan 9, 2025
NCT04630353
A Study HB-201 in Patients With Newly Diagnosed HPV16+ Oropharynx or Locally Advanced Cervical Cancer
Phase: Early Phase 1
Start: Jul 28, 2021
Completion: Nov 28, 2023
NCT05553639
HB-302/HB-301 Therapy in Participants With Metastatic Castration-Resistant Prostate Cancer
Start: May 23, 2023
Completion: Apr 29, 2024
NCT06373380
A Study of HB-202/HB-201 in People With Human Papilloma Virus 16-Positive Head and Neck Squamous Cell Cancer (HPV 16+ HNSCC)
Role: Collaborator
Start: Apr 15, 2024
Completion: Apr 30, 2027
NCT06771674
Real-world Study of First Line Pembrolizumab- or Nivolumab-treated HPV-positive Recurrent/Metastatic Oropharyngeal Squamous Cell Carcinoma
Phase: N/A
Start: Jun 5, 2024
Completion: Feb 28, 2025
NCT06430905
Safety, Reactogenicity and Immunogenicity of HB-502 and HB-501 Versus Placebo in People With HIV on Suppressive ART
Start: Jul 1, 2024
Completion: Nov 30, 2025
NCT06513884
A Study of HB-202/HB-201 With Pembrolizumab in Patients With HPV16+ Recurrent/Metastatic Oropharyngeal Cancer
Phase: Phase 2/3
Start: Dec 31, 2024
Completion: Apr 30, 2032